Gao Xian-Shu
Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, PR China.
Chin J Cancer. 2010 Oct;29(10):860-4. doi: 10.5732/cjc.010.10251.
Esophageal carcinoma is one of the most common malignant tumors, especially in China which is the high incidence area. As a result of mild symptoms of early-stage esophageal cancer, the majority of patients cannot be diagnosed until they develop to advanced cancer, and the treatment outcome of surgery or chemoradiotherapy is still unsatisfactory at present. The guidelines of esophageal cancer issued by National Comprehensive Cancer Network (NCCN) are regarded as important reference tools by clinical oncologists, and provide uniform criteria for the diagnosis and treatment of esophageal carcinoma. However, the guidelines are not always suitable for Chinese patients because the data come from European and American population which have significant ethnical difference from Chinese. We retrospectively analyzed the changes of treatment strategy of esophageal cancer in NCCN guidelines and the advance of treatment for esophageal carcinoma in China, aiming to provide our oncologists with new research ideas. We also hope to set up clinical cancer cooperation organizations, and release our own cancer guidelines to serve Chinese patients and oncologists.
食管癌是最常见的恶性肿瘤之一，在中国这个高发地区尤为如此。由于早期食管癌症状较轻，大多数患者直到发展为晚期癌症才被诊断出来，目前手术或放化疗的治疗效果仍不尽人意。美国国立综合癌症网络（NCCN）发布的食管癌指南被临床肿瘤学家视为重要的参考工具，为食管癌的诊断和治疗提供了统一标准。然而，这些指南并不总是适用于中国患者，因为数据来自欧美人群，与中国人存在显著的种族差异。我们回顾性分析了NCCN指南中食管癌治疗策略的变化以及中国食管癌治疗的进展，旨在为我们的肿瘤学家提供新的研究思路。我们还希望建立临床癌症合作组织，并发布我们自己的癌症指南，为中国患者和肿瘤学家服务。
